Erisyon Inc. is commercializing the world’s first single-molecule
protein sequencer that promises to transform the way we
detect, treat, and track disease.
Inheriting over a decade of work performed at the University of
Texas at Austin’ s Center for Systems and Synthetic Biology,
Erisyon was founded in March 2018 by a group of technologists
and entrepreneurs with the ambition to usher in new discoveries
that make the world healthier, safer, and more abundant.